Results of Adjunctive Intraoperative Bevacizumab Injection on Trabeculectomy Outcome
- Registration Number
- NCT01263834
- Lead Sponsor
- Prince of Songkla University
- Brief Summary
The purpose of this study is to evaluate the adjunctive effect of intratenon Bevacizumab on the result of trabeculectomy in primary term of intraocular pressure (IOP).
- Detailed Description
Prospective interventional clinical trial
Single center, outcome assessor-masked, active control, randomized controlled trial
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 39
Inclusion Criteria
- Primary open angle glaucoma with primary mmc-trabeculectomy indication
Exclusion Criteria
- combined phacoemulsification with trabeculectomy
- no more than 6 month of cataract surgery before trabeculectomy
- revised trabeculectomy
- active uveitic glaucoma
- neovascular glaucoma
- par planar vitrectomy
- conjunctival surgery
- allergy to bevacizumab or mitomycin C
- ischemic heart disease
- cerebrovascular disease
- renal failure
- liver failure
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Mitomycin c Mitomycin C Mitomycin C soaked cellulose dose 0.4 mg/ml with 3 minutes of application Bevacizumab Bevacizumab Bevacizumab injection of 1.25m/0.05 cc + Mitomycin C soaked cellulose dose 0.4 mg/ml with 3 minutes of application
- Primary Outcome Measures
Name Time Method Intraocular pressure 6 month
- Secondary Outcome Measures
Name Time Method systemic Blood pressure 6 months Bleb characteristic grading 6 month
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie Bevacizumab's effect on trabecular meshwork in glaucoma filtration surgery?
How does intraoperative Bevacizumab compare to Mitomycin C in reducing post-trabeculectomy scarring and improving IOP control?
Are there specific ocular biomarkers that predict response to Bevacizumab adjunctive therapy in primary glaucoma patients?
What are the long-term safety profiles of intraoperative Bevacizumab versus Mitomycin C in glaucoma filtration procedures?
How do anti-VEGF agents like Bevacizumab and Ranibizumab synergize with traditional glaucoma therapies in surgical outcomes?
Trial Locations
- Locations (1)
Glaucoma unit , Department of Ophthalmology Faculty of Medicine Prince of Songkla University
🇹🇭Hat-yai, Songkhla, Thailand
Glaucoma unit , Department of Ophthalmology Faculty of Medicine Prince of Songkla University🇹🇭Hat-yai, Songkhla, Thailand